CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene…
NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- EmblemHealth, one of the largest not-for-profit health insurers in the nation, today…
Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial…
Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust…
October 25, 2025 11:01 ET | Source: Cullinan Therapeutics, Inc. CLN-978 led to rapid and deep B cell depletion in…
October 24, 2025 12:00 ET | Source: Flare Therapeutics Inc. FX-909, the first small molecule targeting PPARG to be tested…
– QTX3034 monotherapy and the QTX3034-cetuximab combination demonstrated favorable safety profiles and clear clinical proof of concept, including confirmed responses…
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response…
October 19, 2025 10:00 ET | Source: AVACTA GROUP PLC Median progression free survival (PFS) has not been reached in…
October 19, 2025 08:00 ET | Source: RAPT Therapeutics, Inc. SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) --…